Compugen presented a batch of data from early-stage trials of its anti-PVRIG candidate in dual and triple combination studies, including one with an anti-TIGIT therapy, but the pairings are no longer part of the biotech’s strategy after it recently axed a yearslong Bristol Myers Squibb collaboration.
And, for a brief period this fall, the indication was not a focus of the biotech’s future development plans, but Tuesday’s data are enough to shore up confidence for another study in platinum resistant ovarian cancer, the Holon, Israel-based drug developer said Tuesday.
In one of the studies partially presented Tuesday, Compugen paired its asset, COM701, with Bristol Myers’ Opdivo and anti-TIGIT BMS-986207 in patients with platinum resistant ovarian cancer.
As of Nov. 23, the biotech observed four confirmed partial responses out of 20 patients who had a median number of four prior therapies. Three of those four patients were responding “for at least…
Click here to view original post